Alterity Therapeutics Limited
PRNAF
$0.40
$0.0514.29%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -77.37% | -76.98% | 75.84% | 70.46% | 75.89% |
| Total Revenue | -77.37% | -76.98% | 75.84% | 70.46% | 75.89% |
| Cost of Revenue | 175.61% | 179.60% | 56.52% | 51.64% | -47.03% |
| Gross Profit | -81.66% | -81.35% | 76.64% | 71.22% | 83.08% |
| SG&A Expenses | 168.09% | 172.70% | 55.66% | 50.91% | -21.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 225.51% | 230.21% | 241.30% | 231.22% | 1,860.00% |
| Total Operating Expenses | 51.76% | 54.37% | 45.86% | 41.41% | -29.51% |
| Operating Income | -121.28% | -125.09% | -39.49% | -35.22% | 46.70% |
| Income Before Tax | -201.01% | -206.19% | -34.15% | -30.06% | 62.06% |
| Income Tax Expenses | -17.89% | -16.43% | -- | -- | 43.42% |
| Earnings from Continuing Operations | -198.00% | -203.13% | -35.02% | -30.89% | 61.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -198.00% | -203.13% | -35.02% | -30.89% | 61.67% |
| EBIT | -121.28% | -125.09% | -39.49% | -35.22% | 46.70% |
| EBITDA | -121.62% | -125.43% | -39.77% | -35.50% | 46.72% |
| EPS Basic | -103.74% | -109.62% | 29.55% | 31.42% | 75.35% |
| Normalized Basic EPS | -43.16% | -45.16% | 29.93% | 31.91% | 64.81% |
| EPS Diluted | -111.21% | -116.35% | 32.02% | 34.04% | 75.35% |
| Normalized Diluted EPS | -43.16% | -45.16% | 29.93% | 31.91% | 64.81% |
| Average Basic Shares Outstanding | 45.31% | 45.31% | 91.58% | 91.58% | 56.02% |
| Average Diluted Shares Outstanding | 45.31% | 45.31% | 91.58% | 91.58% | 56.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |